The potential of magnesium sulfate to change serum lysyl oxidase and nitrite level in patients with atherosclerosis: A double-blind clinical trial study

Background: lysyl oxidase (LOX) and magnesium contribute to vascular development and stability. So, this research describes the therapeutic role of magnesium sulfate (MgSO4) in patient with moderate coronary artery disease (CAD) through regulating the serum levels of LOX and nitric oxide. Methods: A randomized double blind placebo-controlled clinical trial with 76 moderate CAD patients divided into four groups. They randomized to use of capsules containing placebo or MgSO4 (300mg) daily during 6 months. So experiments are designed to include Mg-treated- groups with 1and 2 atherosclerotic plaque (Mg-VR1, and Mg -VR2) and placebo-treated- participants with 1 and 2 atherosclerotic plaque (placebo -VR1, placebo -VR2). Every 3 months, LOX, homocysteine, nitrite, and lipid profiles levels were measured. The women and men with moderate CAD who had age of more than 55 and 50 years respectively were included. Results: Total cholesterol and TG (triglycerides) was significantly decreased 6 months after intervention (p<0. 01). Decrease of serum homocysteine level was seen in all groups during the study but the reduction in placebo groups were more than Mg- treated groups (p<0.001). 3months after treatment with MgSO4, LOX was maintained in high levels and returns to base line at 6 months follow up (p<0.001). The rise of nitrite level in placebo -VR2 groups was significantly greater than Mgso4-VR2 treatment (p<0.001). Conclusion: magnesium sulfate may prevent the progression of arteriosclerosis through modulating LOX and homocysteine level and prevent increasing of nitrite level. This randomized study has been approved by Iranian Registry of Clinical Trials with IRCT20151028024756N3 code